Patient or population: people infected with mpox Setting: USA, Canada, Democratic Republic of Congo, Brazil, Switzerland Intervention: tecovirimat Comparison: placebo
Outcomes	Anticipated absolute effects (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Certainty of the evidence (GRADE)	Comment
	Risk with placebo	Risk with tecovirimat
Serious adverse events	‐	‐	‐	‐	‐	‐
Development of complications (proctitis, urethritis, ophthalmic complications)	‐	‐	‐	‐	‐	‐
Admission to hospital	‐	‐	‐	‐	‐	‐
Pain	‐	‐	‐	‐	‐	‐
Risk of onward transmission	‐	‐	‐	‐	‐	‐
Time to healing of all skin lesions “re‐epithelialization”	‐	‐	‐	‐	‐	‐
Mortality	‐	‐	‐	‐	‐	‐